Besides from beneficial effects on parameters such as glucose concentration, weight, blood pressure and albuminuria, SGLT-2 inhibitors potentially reduce the risk of cardiovascular mortality and HF [38]. This evidence concerns the gene SLC5A2 and hydrops fetalis.